Novo’s Wegovy® Shows Promise in Reducing Food Noise in Adults with Obesity

Exploring Wegovy® and Its Impact on Food Noise

At the recent ObesityWeek® 2026, Novo Nordisk unveiled groundbreaking findings from real-world studies indicating that their medication, Wegovy® (semaglutide), significantly diminishes so-called food noise among adults struggling with obesity. Food noise is characterized by persistent and intrusive thoughts about food, which can adversely affect a person's ability to manage their weight and well-being.

Study Insights

The results stem from two sizeable studies, SIGNAL and OCTANE, that analyzed the behavior of individuals who began semaglutide treatment. The SIGNAL study involved 26,213 adults who had previously not undergone any weight-management treatment. These participants tracked their food noise scores using a validated tool called the RO Allison Indiana Dhurandhar–Food Noise Inventory (RAID-FN).

Initial findings revealed a statistically significant reduction in food noise scores from the baseline within the first month of treatment, continuing to see improvements even at the six-month mark. Specifically, there was an average decrease of 0.42 points in the first month, culminating in a total decrease of 0.72 points after six months.

In a parallel study, OCTANE, which followed 7,669 adults who were taking oral semaglutide, also identified a notable reduction in food noise—by approximately 25% in just three months.

Implications of Food Noise

Louis J. Aronne, MD, the Director of the Comprehensive Weight Control Center at Weill Cornell Medicine, commented on the impact of food noise from a clinical perspective. He noted that many patients express these persistent and often intrusive thoughts about food, which can significantly disrupt their daily lives. These studies signify a pivotal shift in addressing obesity, highlighting the importance of not just physical weight loss, but also the management of psychological aspects like food noise.

Real-World Benefits

As the studies unfolded, they shed light on the broader outcomes associated with semaglutide treatment. According to the participants, common enhancements included better-fitting clothes (reported by 67.5%), improved energy levels (26.6%), and even better sleep (18.6%). It is clear that the advantages of Wegovy® extend beyond mere weight-loss metrics; they delve into the everyday experiences of individuals living with obesity.

The interim head of clinical development at Novo, Michelle Skinner Moore, emphasized that while food noise remains a relatively new area of research within obesity management, these findings are crucial. They elevate the conversation toward understanding how GLP-1 medications can influence not just weight loss, but also patients’ lives holistically.

The Future of Obesity Care

Looking ahead, further research is necessary to uncover the clinical implications of food noise and the evolving role it plays in obesity treatment strategies. The studies presented at ObesityWeek® promote the premise that effective obesity care lies in understanding the multifaceted experiences of those who suffer from this condition. It suggests that effective treatments should not only target physical changes but also consider the psychological and emotional challenges that accompany obesity.

As society progresses in its approaches to obesity, initiatives that incorporate patient feedback and real-world experiences, such as those reported by the SIGNAL and OCTANE studies, are pivotal. Such frameworks will potentially transform the landscape of obesity management as healthcare professionals aim for comprehensive care that truly resonates with the needs of patients.